Efficacy and safety of tranexamic acid in non-cardiac arterial procedures: a systematic review and meta-analysis.

IF 1.4 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Annals of vascular surgery Pub Date : 2025-03-27 DOI:10.1016/j.avsg.2025.03.015

T A H Steunenberg, N C Bakker, A M Wiersema, E Tournoij, K K Yeung, V Jongkind

{"title":"Efficacy and safety of tranexamic acid in non-cardiac arterial procedures: a systematic review and meta-analysis.","authors":"T A H Steunenberg, N C Bakker, A M Wiersema, E Tournoij, K K Yeung, V Jongkind","doi":"10.1016/j.avsg.2025.03.015","DOIUrl":null,"url":null,"abstract":"Objectives: Non-cardiac arterial procedures (NCAP) are associated with a high risk of bleeding. Tranexamic acid (TXA) is used among surgical disciplines to reduce blood loss, however its effectiveness and safety in NCAP remain unclear. This review evaluates the efficacy and safety of TXA during NCAP.Methods: Systematic review and meta-analysis was performed in accordance with PRISMA guidelines. Literature searches in PubMed, EMBASE, and Cochrane databases (October 2023 and October 2024) identified studies investigating TXA in open and endovascular NCAP. Meta-analyses were conducted using Cochrane's Review Manager.Results: Five studies (n=4304) were identified. One randomized controlled trial of TXA in non-cardiac surgery (n=9535), including a vascular cohort (14.8%; n=699 TXA, n=700 placebo), showed lower composite bleeding outcomes in the overall cohort receiving TXA (9.5% vs 11.7%; p<0.001), but not in the vascular cohort (HR 0.85; 95%CI 0.64-1.13). Another trial found no difference in blood loss or transfusion rates in 100 patients undergoing open abdominal aortic aneurysm surgery. Both trials reported no increased cardiovascular or thrombo-embolic complications (TEC) or 30-day mortality. A prospective study showed similar thrombosis-related technical failure rates in traumatic vascular injury patients (TXA 6.3% vs 3.8%, p=0.14) and no significant differences in bleeding or hematoma (TXA 11.4% vs 4.3%, p=0.13). In 297 carotid endarterectomy (CEA) patients, TXA significantly reduced postoperative hematoma (7.9% vs 1.3%; p=0.01) without increasing TEC or stroke. TXA during an intraoperative hemostasis protocol during CEA (TXA n=8) reported similar results. Meta-analysis showed no significant differences in TEC (RR 1.10; 95%CI 0.71-1.70) or reoperation rates (RR 0.55; 95%CI 0.19-1.63).Conclusion: TXA does not increase the risk of TEC in NCAP. However, there is currently insufficient evidence that TXA reduces bleeding complications.","PeriodicalId":8061,"journal":{"name":"Annals of vascular surgery","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of vascular surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.avsg.2025.03.015","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Non-cardiac arterial procedures (NCAP) are associated with a high risk of bleeding. Tranexamic acid (TXA) is used among surgical disciplines to reduce blood loss, however its effectiveness and safety in NCAP remain unclear. This review evaluates the efficacy and safety of TXA during NCAP.

Methods: Systematic review and meta-analysis was performed in accordance with PRISMA guidelines. Literature searches in PubMed, EMBASE, and Cochrane databases (October 2023 and October 2024) identified studies investigating TXA in open and endovascular NCAP. Meta-analyses were conducted using Cochrane's Review Manager.

Results: Five studies (n=4304) were identified. One randomized controlled trial of TXA in non-cardiac surgery (n=9535), including a vascular cohort (14.8%; n=699 TXA, n=700 placebo), showed lower composite bleeding outcomes in the overall cohort receiving TXA (9.5% vs 11.7%; p<0.001), but not in the vascular cohort (HR 0.85; 95%CI 0.64-1.13). Another trial found no difference in blood loss or transfusion rates in 100 patients undergoing open abdominal aortic aneurysm surgery. Both trials reported no increased cardiovascular or thrombo-embolic complications (TEC) or 30-day mortality. A prospective study showed similar thrombosis-related technical failure rates in traumatic vascular injury patients (TXA 6.3% vs 3.8%, p=0.14) and no significant differences in bleeding or hematoma (TXA 11.4% vs 4.3%, p=0.13). In 297 carotid endarterectomy (CEA) patients, TXA significantly reduced postoperative hematoma (7.9% vs 1.3%; p=0.01) without increasing TEC or stroke. TXA during an intraoperative hemostasis protocol during CEA (TXA n=8) reported similar results. Meta-analysis showed no significant differences in TEC (RR 1.10; 95%CI 0.71-1.70) or reoperation rates (RR 0.55; 95%CI 0.19-1.63).

Conclusion: TXA does not increase the risk of TEC in NCAP. However, there is currently insufficient evidence that TXA reduces bleeding complications.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of vascular surgery 医学-外科

CiteScore

3.00

自引率

13.30%

发文量

603

审稿时长

50 days

期刊介绍： Annals of Vascular Surgery, published eight times a year, invites original manuscripts reporting clinical and experimental work in vascular surgery for peer review. Articles may be submitted for the following sections of the journal: Clinical Research (reports of clinical series, new drug or medical device trials) Basic Science Research (new investigations, experimental work) Case Reports (reports on a limited series of patients) General Reviews (scholarly review of the existing literature on a relevant topic) Developments in Endovascular and Endoscopic Surgery Selected Techniques (technical maneuvers) Historical Notes (interesting vignettes from the early days of vascular surgery) Editorials/Correspondence